Intelligence Platform

Patents

Browse 126 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 12378558

RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical composi

Arrowhead Pharmaceuticals, Inc. · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12365899

RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12365897

RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and met

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221610

RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and me

Arrowhead Pharmaceuticals, Inc. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12188017

Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173086

Alpha-v beta-6 integrin ligands and uses thereof

Arrowhead Pharmaceuticals, Inc. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12116573

Targeting ligands for therapeutic compounds

Arrowhead Pharmaceuticals, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12110492

RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical comp

Arrowhead Pharmaceuticals, Inc. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091661

Organic compositions to treat HSF1-related diseases

Arrowhead Pharmaceuticals, Inc. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12065458

Trialkyne linking agents and methods of use

Arrowhead Pharmaceuticals, Inc. · Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12054718

RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and

Arrowhead Pharmaceuticals, Inc. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11920134

Compositions and methods for inhibiting expression of RRM2 genes

Arrowhead Pharmaceuticals, Inc. · Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11912997

RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions there

Arrowhead Pharmaceuticals, Inc. · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11884920

Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845937

RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use

Arrowhead Pharmaceuticals, Inc. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11840688

Compositions and methods for inhibiting gene expression of Hif2alpha

Arrowhead Pharmaceuticals, Inc. · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11629349

RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical comp

Arrowhead Pharmaceuticals, Inc. · Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597701

Integrin ligands and uses thereof

Arrowhead Pharmaceuticals, Inc. · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11590156

RNAi agents for hepatitis B virus infection

Arrowhead Pharmaceuticals, Inc. · Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11549112

RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical comp

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11534453

RNAi therapy for hepatitis B virus infection

Arrowhead Pharmaceuticals, Inc. · Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11517584

RNAi agents for Hepatitis B virus infection

Arrowhead Pharmaceuticals, Inc. · Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11492624

RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1

Arrowhead Pharmaceuticals, Inc. · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11384355

Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted